Studi kaitkan obat GLP-1 dengan penurunan risiko kanker payudara

Sabtu, 06 Juni 2026

Dilaporkan oleh AI

Dalam sebuah studi observasional berskala besar, wanita yang mengonsumsi obat GLP-1 seperti Ozempic dan Wegovy menunjukkan kemungkinan terkena kanker payudara sekitar 30 persen lebih rendah.

Para peneliti meninjau rekam medis elektronik dari lebih dari 111.000 wanita berusia 45 hingga 80 tahun dengan indeks massa tubuh 25 atau lebih yang menjalani pencitraan payudara di Penn Medicine antara Januari 2022 dan Juni 2025. Mereka yang diresepkan obat GLP-1 memiliki kemungkinan terkena kanker payudara 35,1 persen lebih rendah pada kelompok penuh dan 30,5 persen lebih rendah dalam analisis yang disesuaikan. Temuan tersebut dipresentasikan pada Pertemuan Tahunan American Society of Clinical Oncology 2026 dan diterbitkan dalam JCO Oncology Practice. Elizabeth McDonald, seorang profesor di Perelman School of Medicine, University of Pennsylvania, mencatat bahwa studi tersebut bersifat observasional dan tidak membuktikan hubungan sebab akibat. McDonald dan rekan-rekannya berencana untuk meluncurkan uji klinis guna menguji apakah obat GLP-1 dapat membantu mencegah kanker payudara pada wanita berisiko tinggi. Obat-obatan tersebut memengaruhi jalur yang terkait dengan perkembangan kanker, meskipun penurunan berat badan juga dapat berkontribusi terhadap manfaat yang teramati.

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Selasa, 05 Mei 2026 Dilaporkan oleh AI Gambar dihasilkan oleh AI Fakta terverifikasi

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Study links Ozempic to lower depression and anxiety risks

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Kamis, 21 Mei 2026 Dilaporkan oleh AI Fakta terverifikasi

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

Kesehatan

Semaglutide shows strong weight loss results for adults over 65

Kesehatan

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

Teknologi

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

Teddi Mellencamp sought weight-loss meds amid stage 4 cancer battle

Teddi Mellencamp, the Real Housewives of Beverly Hills alum, spilled on her podcast that she begged her doctor for GLP-1 weight-loss drugs while battling cancer. She gained weight from steroids but got shut down. Joking about the irony, she quipped about living her best life without the meds.

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Rabu, 01 April 2026 Dilaporkan oleh AI

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Researchers at Vanderbilt Health discovered that both popular weight loss drugs and bariatric surgery significantly reduce fat mass while causing modest losses in fat-free mass, including muscle, in patients with obesity. The findings, based on over 3,000 patients, show improvements in overall body composition over 24 months. Maintaining this balance is crucial for long-term health, the study emphasizes.

05 Juni 2026 14.44